Clobazam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Clobazam Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
41
Registered trials
24
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Clobazam can convert its Small molecule drug profile and GABAA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Clobazam (query alias: clobazam) |
|---|---|
| Modality / target | Small molecule drug; GABAA receptor; GABAA receptor agonists |
| Highest global status | Approved |
| Originator | Sanofi-Aventis Australia Pty Ltd. |
| Active developers | Sumitomo Pharma Co., Ltd., Lundbeck Pharmaceuticals Ltd., Cosette Pharmaceuticals, Inc. |
The MCP disease footprint includes Lennox Gastaut Syndrome, Seizures, Anxiety Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20243975 | Phase 4 | 已完成 | 124 | Not disclosed |
| ChiCTR2400095079 | Phase 4 | Recruiting | 50 | Frequency of seizures |
| IRCT20220211053992N49 | Not Applicable | Pending | 24 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: cannabidiol use = more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group. ; cannabidiol use = more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group.
Clobazam as an add-on treatment for medically refractory brain tumor-related epilepsy.
Not Applicable; n=48; evaluation: Positive. Reported fields: Seizure freedom rate = 68.8 %
Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial
Not Applicable; n=45; evaluation: Positive. Reported fields: Adverse Event: Adverse events = Adverse events occurred in 45% of children who received corticosteroids, most frequently weight gain, and in 52% of children who received clobazam, most often fatigue and behavioural disturbances. Occurrence of adverse events did not differ between groups (RR 0.8, 95% CI 0.4-1.4; p=0.65)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Clobazam addresses Lennox Gastaut Syndrome, Seizures, Anxiety Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-08 | Assertio signed and closed an agreement to sell all non-Rolvedon assets to Cosette Pharmaceuticals | Approved | US$35.0M upfront |
| 2022-10-27 | Assertio Holdings has acquired an exclusive license for Sympazan oral film from Aquestive Therapeutics | Approved | US$9.0M upfront; US$6.0M milestones |
| 2018-11-02 | Ashfield Healthcare partners with Aquestive to market the clobazam oral film for treating seizures related to Lennox-Gastaut syndrome. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Clobazam formulation in capsule form”. The milestone feed surfaced a patent-application signal described as “Preparation method of clobazam oral suspension”. The milestone feed surfaced a patent-application signal described as “Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
